The Application of a Reduced Dye Used in Orthopedics as a Novel Treatment against Coronavirus (COVID-19): A Suggested Therapeutic Protocol (2020)

Peer-Reviewed Study · Hamidi Alamdari D; Bagheri Moghaddam A; Amini S; Hamidi Alamdari A; Damsaz M; Yarahmadi A · April 2020

Hamidi Alamdari D et al., 2020-04: Protocol paper from the Iranian group proposing intravenous leucomethylene blue (reduced methylene blue) with vitamin C and N-acetylcysteine for COVID-19, with the exact cocktail, dilution and preparation steps.

The IV cocktail contains 50 mg MB (1mg/kg, 50-kg weight), 1000-2000 mg vitamin C, 500-1000 mg N-Acetylcysteine (or glutathione or cysteine or α-lipoic acid) and 10-20 gr urea (optional) in 100 ml dextrose 5%.

Abstract (protocol text)

Hamidi Alamdari D et al., 2020-04: Protocol paper from the Iranian group proposing intravenous leucomethylene blue (reduced methylene blue) with vitamin C and N-acetylcysteine for COVID-19, with the exact cocktail, dilution and preparation steps. Study type: therapeutic protocol proposal (no patients, no data). Country: Iran (Mashhad University of Medical Sciences). Dose recorded in full as published: 50 mg MB (1 mg/kg for a 50 kg patient), 1000-2000 mg vitamin C, 500-1000 mg NAC (or glutathione/cysteine/alpha-lipoic acid), 10-20 g urea optional, in 100 mL dextrose 5%, kept in the dark 1-2 h until the solution fades. Route: IV. Note for the verifier: this is a proposal, not evidence of effect; it is the source of the protocol later used in the group's trials. Funder/COI not stated in the retrieved abstract record. Study type: other.